Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study

References

• Li J, Huang DQ, Zou B et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449–1458. doi:10.1002/jmv.26424
   PubMed Web of Science ®Google Scholar
• Guiso N. Impact de la vaccination sur l’épidémiologie des maladies infectieuses : exemple de la coqueluche. [Impact of vaccination on the infectious diseases epidemiology: example of pertussis]. Med Sci. 2007;23(4):399–403. French. doi:10.1051/medsci/2007234399
   Web of Science ®Google Scholar
• Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3(1):73–78. doi:10.4103/0974-777X.77299
   PubMedGoogle Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100. doi:10.1038/s41577-020-00479-7
   PubMed Web of Science ®Google Scholar
• Lee S, Ryu JH. Influenza viruses: innate immunity and mRNA vaccines. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.710647
   Web of Science ®Google Scholar
• Platt A, Wetzler L. Innate immunity and vaccines. Curr Top Med Chem. 2013;13(20):2597–2608. doi:10.2174/15680266113136660185
   PubMed Web of Science ®Google Scholar
• Jiskoot W, Kersten GFA, Mastrobattista E, Slütter B. Vaccines. In: Crommelin DJA, Sindelar RD, Meibohm B, editors. Pharmaceutical Biotechnology: Fundamentals and Applications. Springer International Publishing; 2019:281–304.
   Google Scholar
• Casado JL, Haemmerle J, Vizcarra P, et al. T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity. Clin Transl Immunol. 2021;10(9):e1341. doi:10.1002/cti2.1341
   PubMed Web of Science ®Google Scholar
• Almendro-Vázquez P, Laguna-Goya R, Ruiz-Ruigomez M, et al. Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination. PLoS Pathog. 2021;17(12):e1010211. doi:10.1371/journal.ppat.1010211
   PubMed Web of Science ®Google Scholar
• Dunn-Walters DK, Stewart AT, Sinclair EL, Serangeli I. Age-related changes in B cells relevant to vaccine responses. Interdiscip Top Gerontol Geriatr. 2020;43:56–72.
   PubMedGoogle Scholar
• Diks AM, Overduin LA, Van Leenen LD, et al. B-cell immunophenotyping to predict vaccination outcome in the immunocompromised - A systematic review. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.690328
   Web of Science ®Google Scholar
• Martin VG, Wu YCB, Townsend CL, et al. Transitional B cells in early human B cell development – time to revisit the paradigm? Front Immunol. 2016;7. doi:10.3389/fimmu.2016.00546
   Web of Science ®Google Scholar
• Zhou Y, Zhang Y, Han J, Yang M, Zhu J, Jin T. Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases. J Transl Med. 2020;18(1):131. doi:10.1186/s12967-020-02289-w
   PubMed Web of Science ®Google Scholar
• Sagaert X, Sprangers B, De Wolf-Peeters C. The dynamics of the B follicle: understanding the normal counterpart of B-cell-derived malignancies. Leukemia. 2007;21(7):1378–1386. doi:10.1038/sj.leu.2404737
   PubMed Web of Science ®Google Scholar
• Palm AKE, Henry C. Remembrance of things past: long-term B cell memory after infection and vaccination. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.01787
   PubMed Web of Science ®Google Scholar
• Mitchell R, Kelly DF, Pollard AJ, Trück J. Polysaccharide-specific B cell responses to vaccination in humans. Hum Vaccin Immunother. 2014;10(6):1661–1668. doi:10.4161/hv.28350
   PubMed Web of Science ®Google Scholar
• Ellebedy AH, Jackson KJL, Kissick HT, et al. Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. Nat Immunol. 2016;17(10):1226–1234. doi:10.1038/ni.3533
   PubMed Web of Science ®Google Scholar
• Sanz I, Wei C, Jenks SA, et al. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.02458
   Web of Science ®Google Scholar
• Li Y, Li Z, Hu F. Double-negative (DN) B cells: an under-recognized effector memory B cell subset in autoimmunity. Clin Exp Immunol. 2021;205(2):119–127. doi:10.1111/cei.13615
   PubMed Web of Science ®Google Scholar
• van Zelm MC, Szczepanski T, van der Burg M, van Dongen JJM. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. J Exp Med. 2007;204(3):645–655. doi:10.1084/jem.20060964
   PubMed Web of Science ®Google Scholar
• Blanco E, Pérez-Andrés M, Arriba-Méndez S, et al. Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. J Allergy Clin Immunol. 2018;141(6):2208–2219.e16. doi:10.1016/j.jaci.2018.02.017
   PubMed Web of Science ®Google Scholar
• Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111(8):3941–3967. doi:10.1182/blood-2007-11-120535
   PubMed Web of Science ®Google Scholar
• Kent SJ, Juno JA. Vaccination after prior COVID-19 infection: implications for dose sparing and booster shots. eBioMedicine. 2021;72:103586. doi:10.1016/j.ebiom.2021.103586
   PubMed Web of Science ®Google Scholar
• Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med. 2022;386(13):1207–1220. doi:10.1056/NEJMoa2118691
   PubMed Web of Science ®Google Scholar
• Hammerman A, Sergienko R, Friger M, et al. Effectiveness of the BNT162b2 vaccine after recovery from Covid-19. N Engl J Med. 2022;386(13):1221–1229. doi:10.1056/NEJMoa2119497
   PubMed Web of Science ®Google Scholar
• Dalle Carbonare L, Valenti MT, Bisoffi Z, et al. Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve. Commun Med. 2021;1(1):1–11. doi:10.1038/s43856-021-00039-7
   PubMedGoogle Scholar
• Morales-Núñez JJ, Muñoz-Valle JF, Meza-López C, et al. Neutralizing antibodies titers and side effects in response to BNT162b2 vaccine in healthcare workers with and without prior SARS-CoV-2 infection. Vaccines. 2021;9(7):742. doi:10.3390/vaccines9070742
   Web of Science ®Google Scholar
• Ciabattini A, Pastore G, Fiorino F, et al. Evidence of SARS-CoV-2-specific memory B cells six months after vaccination with the BNT162b2 mRNA vaccine. Front Immunol. 2021;12:3751. doi:10.3389/fimmu.2021.740708
   Web of Science ®Google Scholar
• Giannotta G, Giannotta N. mRNA COVID-19 vaccines and long-lived plasma cells: a complicated relationship. Vaccines. 2021;9(12):1503. doi:10.3390/vaccines9121503
   Web of Science ®Google Scholar
• Wang H, Paulson KR, Pease SA, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet. 2022;399(10334):1513–1536. doi:10.1016/S0140-6736(21)02796-3
   PubMed Web of Science ®Google Scholar
• Sosa-Hernández VA, Torres-Ruíz J, Cervantes-Díaz R, et al. B cell subsets as severity-associated signatures in COVID-19 patients. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.611004
   PubMed Web of Science ®Google Scholar
• Li S, Ma F, Hao H, et al. Marked elevation of circulating CD19+CD38hiCD24hi transitional B cells give protection against neonatal sepsis. Pediatr Neonatol. 2018;59(3):296–304. doi:10.1016/j.pedneo.2017.10.005
   PubMed Web of Science ®Google Scholar
• Giltiay NV, Giordano D, Clark EA. The plasticity of newly formed B cells. J Immunol. 2019;203(12):3095–3104. doi:10.4049/jimmunol.1900928
   PubMed Web of Science ®Google Scholar
• Oliviero B, Varchetta S, Mele D, et al. Expansion of atypical memory B cells is a prominent feature of COVID-19. Cell Mol Immunol. 2020;17(10):1101–1103. doi:10.1038/s41423-020-00542-2
   PubMed Web of Science ®Google Scholar
• Gobbi F, Buonfrate D, Moro L, et al. Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection. Viruses. 2021;13(3):422. doi:10.3390/v13030422
   PubMed Web of Science ®Google Scholar
• Shahaf G, Zisman-Rozen S, Benhamou D, Melamed D, Mehr R. B cell development in the bone marrow is regulated by homeostatic feedback exerted by mature B cells. Front Immunol. 2016;7:77. doi:10.3389/fimmu.2016.00077
   PubMed Web of Science ®Google Scholar
• Chan TD, Brink R. Affinity-based selection and the germinal center response. Immunol Rev. 2012;247(1):11–23. doi:10.1111/j.1600-065X.2012.01118.x
   PubMed Web of Science ®Google Scholar
• Brewer RC, Ramadoss NS, Lahey LJ, Jahanbani S, Robinson WH, Lanz TV. BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2. Nat Immunol. 2022;23(1):33–39. doi:10.1038/s41590-021-01088-9
   PubMed Web of Science ®Google Scholar
• Schulz E, Hodl I, Forstner P, et al. CD19+IgD+CD27- Naïve B cells as predictors of humoral response to COVID 19 mRNA vaccination in immunocompromised patients. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.803742
   Web of Science ®Google Scholar
• De Biasi S, Lo Tartaro D, Meschiari M, et al. Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia. Eur J Immunol. 2020;50(9):1283–1294. doi:10.1002/eji.202048838
   PubMed Web of Science ®Google Scholar
• Song G. H Wting, Callaghan S et al. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat Commun. 2021;12(1):2938. doi:10.1038/s41467-021-23074-3
   PubMed Web of Science ®Google Scholar
• Amanat F, Thapa M, Lei T, et al. The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD. medRxiv. 2021. doi:10.1101/2021.03.07.21253098
   Google Scholar
• He X-S, Sasaki S, Narvaez CF, et al. Plasmablast-derived polyclonal antibody response after influenza vaccination. J Immunol Methods. 2011;365(1–2):67–75. doi:10.1016/j.jim.2010.12.008
   PubMed Web of Science ®Google Scholar
• Qian Y, Wei C, Eun-Hyung Lee F, et al. Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data. Cytometry B Clin Cytom. 2010;78B(S1):S69–S82. doi:10.1002/cyto.b.20554
   Web of Science ®Google Scholar
• Kardava L, Rachmaninoff N, Lau WW, et al. Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccine. medRxiv. 2021. doi:10.1101/2021.07.06.21259528
   PubMedGoogle Scholar
• Garimalla S, Nguyen DC, Halliley JL, et al. Differential transcriptome and development of human peripheral plasma cell subsets. JCI Insight. 2019;4(9). doi:10.1172/jci.insight.126732.
   PubMed Web of Science ®Google Scholar
• Chan TD, Gatto D, Wood K, Camidge T, Basten A, Brink R. Antigen affinity controls rapid T-dependent antibody production by driving the expansion rather than the differentiation or extrafollicular migration of early plasmablasts. J Immunol. 2009;183(5):3139–3149. doi:10.4049/jimmunol.0901690
   PubMed Web of Science ®Google Scholar
• Jenks SA, Cashman KS, Zumaquero E, et al. Distinct effector B Cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity. 2018;49(4):725–739.e6. doi:10.1016/j.immuni.2018.08.015
   PubMed Web of Science ®Google Scholar
• Ruschil C, Gabernet G, Lepennetier G, et al. Specific induction of double negative B cells during protective and pathogenic immune responses. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.606338
   PubMed Web of Science ®Google Scholar
• Wei C, Anolik J, Cappione A, et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol. 2007;178(10):6624–6633. doi:10.4049/jimmunol.178.10.6624
   PubMed Web of Science ®Google Scholar
• Callegaro A, Borleri D, Farina C, et al. Antibody response to SARS‐CoV‐2 vaccination is extremely vivacious in subjects with previous SARS‐CoV‐2 infection. J Med Virol. 2021;93(7):4612–4615. doi:10.1002/jmv.26982
   PubMed Web of Science ®Google Scholar
• Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;3:1–4.
   Google Scholar
• Goel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol. 2021;6(58). doi:10.1126/sciimmunol.abi6950.
   PubMed Web of Science ®Google Scholar
• Krammer F. ARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–527. doi:10.1038/s41586-020-2798-3
   PubMed Web of Science ®Google Scholar